한빛사논문
Hanna Cho 1,2,3, Nidhi S Mundada 1, Liana G Apostolova 4,5,6, Maria C Carrillo 7, Ranjani Shankar 1, Alinda N Amuiri 1, Ehud Zeltzer 1, Charles C Windon 1, David N Soleimani-Meigooni 1, Jeremy A Tanner 1, Courtney Lawhn Heath 8, Orit H Lesman-Segev 1,9, Paul Aisen 10, Ani Eloyan 11, Hye Sun Lee 12, Dustin B Hammers 4, Kala Kirby 4, Jeffrey L Dage 4, Anne Fagan 13, Tatiana Foroud 6, Lea T Grinberg 1,14, Clifford R Jack 15, Joel Kramer 1, Walter A Kukull 16, Melissa E Murray 17, Kelly Nudelman 6, Arthur Toga 18, Prashanthi Vemuri 15, Alireza Atri 19, Gregory S Day 20, Ranjan Duara 21, Neill R Graff-Radford 20, Lawrence S Honig 22, David T Jones 15,23, Joseph Masdeu 24, Mario Mendez 25, Erik Musiek 13, Chiadi U Onyike 26, Meghan Riddle 27, Emily J Rogalski 28, Stephen Salloway 27, Sharon Sha 29, Raymond Scott Turner 30, Thomas S Wingo 31, David A Wolk 32, Robert Koeppe 33, Leonardo Iaccarino 1, Bradford C Dickerson 34, Renaud La Joie 1, Gil D Rabinovici 1,8; LEADS Consortium 4
1Memory and Aging Center, UCSF Weill Institute for Neurosciences, Department of Neurology, University of California, San Francisco, California, USA.
2Department of Neurology, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, Republic of Korea.
3Global Brain Health Institute, University of California, San Francisco, California, USA.
4Department of Neurology, Indiana University School of Medicine, Indianapolis, Indiana, USA.
5Department of Radiology and Imaging Sciences, Center for Neuroimaging, Indiana University School of Medicine Indianapolis, Indianapolis, Indiana, USA.
6Department of Medical and Molecular Genetics, Indiana University School of Medicine, Indianapolis, Indiana, USA.
7Medical & Scientific Relations Division, Alzheimer's Association, Chicago, Illinois, USA.
8Department of Radiology and Biomedical Imaging, University of California, San Francisco, California, USA.
9Department of Diagnostic Imaging, Sheba Medical Center, Tel HaShomer, Israel.
10Alzheimer's Therapeutic Research Institute, University of Southern California, San Diego, California, USA.
11Department of Biostatistics, Center for Statistical Sciences, Brown University, Rhode Island, USA.
12Biostatistics Collaboration Unit, Yonsei University College of Medicine, Seoul, Republic of Korea.
13Department of Neurology, Washington University in St. Louis, St. Louis, Missouri, USA.
14Department of Pathology, University of California - San Francisco, San Francisco, California, USA.
15Department of Radiology, Mayo Clinic, Rochester, Minnesota, USA.
16Department of Epidemiology, University of Washington, Seattle, Washington, USA.
17Department of Neuroscience, Mayo Clinic, Jacksonville, Florida, USA.
18Laboratory of Neuro Imaging, USC Stevens Neuroimaging and Informatics Institute, Keck School of Medicine of USC, Los Angeles, California, USA.
19Banner Sun Health Research Institute, Sun City, Arizona, USA.
20Department of Neurology, Mayo Clinic, Jacksonville, Florida, USA.
21Wien Center for Alzheimer's Disease and Memory Disorders, Mount Sinai Medical Center, Miami, Florida, USA.
22Taub Institute and Department of Neurology, Columbia University Irving Medical Center, New York, New York, USA.
23Department of Neurology, Mayo Clinic, Rochester, Minnesota, USA.
24Nantz National Alzheimer Center, Houston Methodist and Weill Cornell Medicine, Houston, Texas, USA.
25Department of Neurology, David Geffen School of Medicine at UCLA, Los Angeles, California, USA.
26Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
27Department of Neurology, Alpert Medical School, Brown University, Rhode Island, USA.
28Department of Psychiatry and Behavioral Sciences, Mesulam Center for Cognitive Neurology and Alzheimer's Disease, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA.
29Department of Neurology & Neurological Sciences, Stanford University, Palo Alto, California, USA.
30Department of Neurology, Georgetown University, Washington, USA.
31Department of Neurology and Human Genetics, Emory University School of Medicine, Atlanta, Georgia, USA.
32Department of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
33Division of Nuclear Medicine, Department of Radiology, University of Michigan, Ann Arbor, Michigan, USA.
34Department of Neurology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA.
Hanna Cho and Nidhi S. Mundada contributed equally to this work as first authors
Renaud La Joie and Gil D. Rabinovici contributed equally to this work as last authors
CORRESPONDING AUTHOR : Gil D. Rabinovici
Abstract
Introduction: We aimed to describe baseline amyloid-beta (Aβ) and tau-positron emission tomograrphy (PET) from Longitudinal Early-onset Alzheimer's Disease Study (LEADS), a prospective multi-site observational study of sporadic early-onset Alzheimer's disease (EOAD).
Methods: We analyzed baseline [18F]Florbetaben (Aβ) and [18F]Flortaucipir (tau)-PET from cognitively impaired participants with a clinical diagnosis of mild cognitive impairment (MCI) or AD dementia aged < 65 years. Florbetaben scans were used to distinguish cognitively impaired participants with EOAD (Aβ+) from EOnonAD (Aβ-) based on the combination of visual read by expert reader and image quantification.
Results: 243/321 (75.7%) of participants were assigned to the EOAD group based on amyloid-PET; 231 (95.1%) of them were tau-PET positive (A+T+). Tau-PET signal was elevated across cortical regions with a parietal-predominant pattern, and higher burden was observed in younger and female EOAD participants.
Discussion: LEADS data emphasizes the importance of biomarkers to enhance diagnostic accuracy in EOAD. The advanced tau-PET binding at baseline might have implications for therapeutic strategies in patients with EOAD.
Highlights: 72% of patients with clinical EOAD were positive on both amyloid- and tau-PET. Amyloid-positive patients with EOAD had high tau-PET signal across cortical regions. In EOAD, tau-PET mediated the relationship between amyloid-PET and MMSE. Among EOAD patients, younger onset and female sex were associated with higher tau-PET.
논문정보
관련 링크
연구자 키워드
관련분야 연구자보기
소속기관 논문보기
관련분야 논문보기
해당논문 저자보기